Plexxikon Inc.

Metabolex, Inc.

Cymabay Therapeutics, Inc.

Opna Immuno-oncology Sa

Phuongly Pham

Wayne Spevak

John Buell

Guoxian Wu

Jiazhong Zhang

Ying Zhang

Songyuan Shi

Jack Lin

Jiangao Song

Xin Chen

Jingyuan Ma

Aaron Robert Novack

Imad Nashashibi

Prabha N Ibrahim

Jeffrey Yung Wu

Aaron Edward Albers

Christopher J Rabbat

Zuojun Guo

Dong Fang Shi

Hannah Powers

Katrina Chan

Jack Walleshauser

Dong-Fang Shi

David W G Wone

Jeffrey Wu

Jeffrey D Johnson

Chao Zhang

Charles A McWherter

Marika Nespi

Todd Ewing

Hiroaki Inagaki

Xueyan Wang

Brian Edward Lavan

Elizabeth A Burton

Ken Dong

Garson Tsang

Yongil Jin

Aaron Albers

Aaron Novack

Compounds and methods for EP300 or CBP modulation and indications therefor

Disclosed are compounds of Formula (I) and (Ia): 

Compounds and methods for IDO and TDO modulation, and indications therefor

Compounds and methods for CDK8 modulation and indications therefor

Heterocyclic compounds of formula (I), methods for their preparation, pharmaceutical compositions containing such a compound and their therapeutic uses.

Heterocyclic compounds and uses thereof

Disclosed are compounds of Formula I(a): 

Compounds active on c-kit protein kinases or mutant c-kit protein kinases having any mutations are described, as well as methods of making and using such compounds to treat diseases and conditions associated with aberrant activity of the c-kit protein kinases and mutant c-kit protein kinases.

Compounds and methods for kinase modulation, and indications therefor

Compounds of Formula I: or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer or a deuterated analog thereof, wherein R, R, Q, Q, and Q, are described in this disclosure, compositions thereof, and methods and uses thereof.

Disclosed are compounds of Formula I(b): or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer or a deuterated analog thereof, wherein Ring A, Ring HD, J, each T, R, R, R, each R, and m are as described in any of the embodiments described in this disclosure; compositions thereof; and uses thereof.

Compounds active on c-kit protein kinases or mutant c-kit protein kinases having any mutations are described, wherein the compounds are of Formula (I): Methods of making and using such compounds to treat diseases and conditions associated with aberrant activity of the c-kit protein kinases and/or mutant c-kit protein kinases are also described.

The present disclosure relates to compounds that act as agonists of, or otherwise modulate the activity of, GPR131 and to their use in the treatment of various diseases. In particular embodiments, the structure of the compounds is given by Formula I: wherein the variables are as described herein. Related compositions, formulations and methods for the preparation of compounds of formula I are also described.

Bicyclic agonists of GPR131 and uses thereof

Chemical compounds which act as agonists of, or otherwise modulate the activity of, GPR131 are disclosed. Related compositions, formulations and methods of use are also described.

Agonists of GPR131 and uses thereof

GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.

GPR120 receptor agonists and uses thereof

Growing community of inventors

San Francisco, CA, United States of America

Phuongly Pham